Skip to main content

Sigma-Aldrich Sees 7-Percent Q3 Revenue Growth as Profits Rise 7 Percent

The net income that originally appeared in this article reported earnings for the 9-month period ended Sept. 30 and showed a 2-percent increase year over year. The story has been corrected to reflect profit for the three months ended Sept. 30, which reflect a 7-percent increase.
 
NEW YORK (GenomeWeb News) — Sigma-Aldrich today said that third-quarter revenue increased 7 percent as R&D spending grew and profit inched up 7 percent.
 
Total receipts for the three months ended Sept. 30 increased to $441.4 million from $412 million year over year.
 
“Benefits from the ongoing, global roll-out of new customer centric programs were partially offset by lower than expected improvements in underlying market conditions, particularly in Japan, and by slower than anticipated acceptance of several of our new and innovative Research Biotech products,” CEO Jai Nagarkatti said in a statement.
 
R&D spending rose slightly to $13.2 million.
 
Net income for the period increased to $68.4 million from $63.9 million last year.
 
Sigma said it had around $137 million in cash and equivalents.
 
Sigma said it expects full-year revenue from sales to increase 7 percent year over year, which will include a benefit from the acquisition in February of the JRH cell culture business. It expects organic sales growth to be around 6 percent.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.